Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1998-4-13
|
pubmed:abstractText |
1. The binding of the new selective group II metabotropic glutamate receptor radioligand, [3H]-(2S,2'R,3'R)-2-(2',3'-dicarboxycyclopropyl)glycine ([3H]-DCG IV), was characterized in rat mGlu2 receptor-transfected CHO cell membranes. 2. [3H]-DCG IV binding was pH-dependent, but was not sensitive to temperature. Saturation analysis showed the presence of a single binding site, with a Kd value of 160 nM and a Bmax value of 10 pmol mg(-1) protein. Binding was not sensitive to Na+-dependent glutamate uptake blockers or Cl-dependent glutamate binding inhibitors. Furthermore, up to concentrations of 1 mM, the glutamate ionotropic receptor agonists, N-methyl-D-aspartic acid (NMDA), (S)-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate, did not affect [3H]-DCG IV binding. 3. Of the compounds observed to inhibit [3H]-DCG IV binding, the most potent were the recently described selective group II agonist, (+)-2-aminobicyclo-[3.1.0]hexane-2,6-dicarboxylate (LY 354740; Ki value 16 nM) and antagonist, 2-amino-2-(2-carboxycyclopropan-1-yl)-3-(dibenzopyran-4-yl) propanoic acid (LY 341495; Ki value 19 nM). As expected, for a G-protein-coupled receptor, guanosine-5'-O-(3-thiotriphosphate) (GTPgammaS) inhibited [3H]-DCG IV binding in a concentration-dependent manner, with an IC50 value of 12 nNM. 4. A highly significant correlation was observed between the potencies of compounds able to inhibit [3H]-DCG IV binding and potencies obtained for agonist activity in a GTPgamma35S binding functional assay. In addition, these studies identified a number of compounds with previously unknown activity at mGlu2 receptors, including L(+)-2-amino-3-phosphonopropionic acid (L-AP3), L(+)-2-amino-5-phosphonopentanoic acid (L-AP5), 3-((RS)-2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (R-CPP), N-acetyl-L-aspartyl-L-glutamic acid (NAAG) and (RS)-alpha-methylserine-O-phosphate (MSOP).
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/2-(2,3-dicarboxycyclopropyl)glycine,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclic AMP,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclopropanes,
http://linkedlifedata.com/resource/pubmed/chemical/Forskolin,
http://linkedlifedata.com/resource/pubmed/chemical/Glycine,
http://linkedlifedata.com/resource/pubmed/chemical/Guanosine 5'-O-(3-Thiotriphosphate),
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Metabotropic Glutamate,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Sulfur Radioisotopes,
http://linkedlifedata.com/resource/pubmed/chemical/Tritium
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0007-1188
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
123
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
497-504
|
pubmed:dateRevised |
2008-11-20
|
pubmed:meshHeading |
pubmed-meshheading:9504391-Animals,
pubmed-meshheading:9504391-CHO Cells,
pubmed-meshheading:9504391-Cell Membrane,
pubmed-meshheading:9504391-Cricetinae,
pubmed-meshheading:9504391-Cyclic AMP,
pubmed-meshheading:9504391-Cyclopropanes,
pubmed-meshheading:9504391-Forskolin,
pubmed-meshheading:9504391-Glycine,
pubmed-meshheading:9504391-Guanosine 5'-O-(3-Thiotriphosphate),
pubmed-meshheading:9504391-Protein Binding,
pubmed-meshheading:9504391-Rats,
pubmed-meshheading:9504391-Receptors, Metabotropic Glutamate,
pubmed-meshheading:9504391-Recombinant Proteins,
pubmed-meshheading:9504391-Sulfur Radioisotopes,
pubmed-meshheading:9504391-Transfection,
pubmed-meshheading:9504391-Tritium
|
pubmed:year |
1998
|
pubmed:articleTitle |
Characterization of [3H]-(2S,2'R,3'R)-2-(2',3'-dicarboxy-cyclopropyl)glycine ([3H]-DCG IV) binding to metabotropic mGlu2 receptor-transfected cell membranes.
|
pubmed:affiliation |
Pharma Division Preclinical CNS Research, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
|
pubmed:publicationType |
Journal Article
|